A statement released earlier today by B. Riley about DexCom, Inc. (NASDAQ:DXCM) raises the target price to $97.00
- Updated: October 1, 2016
DexCom, Inc. (NASDAQ:DXCM) had its target price raised to $97.00 by B. Riley in a report released 10/02/2016. The new target price indicates a possible upside of 0.11% based on the company's last stock close price.
Previously on Tuesday September 27, 2016, B. Riley reported about DexCom, Inc. (NASDAQ:DXCM) raised the target price from $0.00 to $97.00. At the time, this indicated a possible upside of 0.04%.
Yesterday DexCom, Inc. (NASDAQ:DXCM) traded -0.16% lower at $87.66. The company’s 50-day moving average is $91.93 and its 200-day moving average is $77.09. The last stock close price is up 13.71% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 1,025,933 shares of the stock exchanged hands, up from an avg. volume of 845,119
See Chart Below
DexCom, Inc. has a 52 week low of $47.92 and a one year high of $96.38 DexCom, Inc.’s market capitalization is currently $0.
Brief Synopsis On DexCom, Inc. (NASDAQ:DXCM)
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile. It had received Conformite Europeene Marking (CE Mark) approval for its fourth generation continuous glucose monitoring system, the DexCom G4 system, enabling commercialization of the DexCom G4 system. DexCom SHARE enables users of its G4 PLATINUM System to have their sensor glucose information remotely monitored by their family or friends. The G4 PLATINUM Receiver with Share uses a secure wireless connection via Bluetooth Low Energy (BLE) between a patient's receiver and a mobile application on the patient's iPhone to transmit glucose information.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.